Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vodobatinib (K0706) in Healthy Subjects and Treatment-Refractory/Intolerant CML or Ph+ ALL
NCT02629692Phase 2Terminated
- Sponsor
- Sun Pharma
- Start
- Jun 2016
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of vodobatinib in chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), sponsored by Sun Pharma. Started Jun 2016; status: terminated.
02
Drugs
vodobatinib
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02629692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629692.